vs

Side-by-side financial comparison of Abbott Laboratories (ABT) and Dow Inc. (DOW). Click either name above to swap in a different company.

Abbott Laboratories is the larger business by last-quarter revenue ($11.5B vs $9.5B, roughly 1.2× Dow Inc.). On growth, Abbott Laboratories posted the faster year-over-year revenue change (4.4% vs -9.3%). Over the past eight quarters, Abbott Laboratories's revenue compounded faster (7.2% CAGR vs -6.9%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

The Dow Chemical Company is an American multinational corporation headquartered in Midland, Michigan, United States. The company was among the three largest chemical producers in the world in 2021. It is the operating subsidiary of Dow Inc., a publicly traded holding company incorporated under Delaware law.

ABT vs DOW — Head-to-Head

Bigger by revenue
ABT
ABT
1.2× larger
ABT
$11.5B
$9.5B
DOW
Growing faster (revenue YoY)
ABT
ABT
+13.7% gap
ABT
4.4%
-9.3%
DOW
Faster 2-yr revenue CAGR
ABT
ABT
Annualised
ABT
7.2%
-6.9%
DOW

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABT
ABT
DOW
DOW
Revenue
$11.5B
$9.5B
Net Profit
$1.8B
Gross Margin
57.0%
5.8%
Operating Margin
19.6%
Net Margin
15.5%
Revenue YoY
4.4%
-9.3%
Net Profit YoY
-80.8%
EPS (diluted)
$1.01
$-2.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABT
ABT
DOW
DOW
Q1 26
$9.5B
Q4 25
$11.5B
$9.5B
Q3 25
$11.4B
$10.0B
Q2 25
$11.1B
$10.1B
Q1 25
$10.4B
$10.4B
Q4 24
$11.0B
$10.4B
Q3 24
$10.6B
$10.9B
Q2 24
$10.4B
$10.9B
Net Profit
ABT
ABT
DOW
DOW
Q1 26
Q4 25
$1.8B
$-1.5B
Q3 25
$1.6B
$62.0M
Q2 25
$1.8B
$-835.0M
Q1 25
$1.3B
$-307.0M
Q4 24
$9.2B
$-35.0M
Q3 24
$1.6B
$214.0M
Q2 24
$1.3B
$439.0M
Gross Margin
ABT
ABT
DOW
DOW
Q1 26
5.8%
Q4 25
57.0%
5.8%
Q3 25
55.4%
7.3%
Q2 25
56.4%
5.8%
Q1 25
56.9%
6.4%
Q4 24
55.0%
9.0%
Q3 24
55.8%
9.8%
Q2 24
55.6%
12.1%
Operating Margin
ABT
ABT
DOW
DOW
Q1 26
Q4 25
19.6%
-16.4%
Q3 25
18.1%
0.7%
Q2 25
18.4%
-6.5%
Q1 25
16.3%
-3.6%
Q4 24
17.4%
2.1%
Q3 24
17.5%
3.0%
Q2 24
16.1%
5.6%
Net Margin
ABT
ABT
DOW
DOW
Q1 26
Q4 25
15.5%
-15.6%
Q3 25
14.5%
0.6%
Q2 25
16.0%
-8.3%
Q1 25
12.8%
-2.9%
Q4 24
84.1%
-0.3%
Q3 24
15.5%
2.0%
Q2 24
12.5%
4.0%
EPS (diluted)
ABT
ABT
DOW
DOW
Q1 26
$-2.16
Q4 25
$1.01
$-2.16
Q3 25
$0.94
$0.08
Q2 25
$1.01
$-1.18
Q1 25
$0.76
$-0.44
Q4 24
$5.26
$-0.08
Q3 24
$0.94
$0.30
Q2 24
$0.74
$0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABT
ABT
DOW
DOW
Cash + ST InvestmentsLiquidity on hand
$8.9B
$3.8B
Total DebtLower is stronger
$12.9B
$17.8B
Stockholders' EquityBook value
$52.1B
$16.0B
Total Assets
$86.7B
$58.5B
Debt / EquityLower = less leverage
0.25×
1.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABT
ABT
DOW
DOW
Q1 26
$3.8B
Q4 25
$8.9B
$3.8B
Q3 25
$7.7B
$4.6B
Q2 25
$7.3B
$2.4B
Q1 25
$6.8B
$1.5B
Q4 24
$8.0B
$2.2B
Q3 24
$7.8B
$2.9B
Q2 24
$7.2B
$3.3B
Total Debt
ABT
ABT
DOW
DOW
Q1 26
$17.8B
Q4 25
$12.9B
$17.8B
Q3 25
$17.7B
Q2 25
$16.2B
Q1 25
$15.9B
Q4 24
$14.1B
$15.7B
Q3 24
$16.2B
Q2 24
$16.0B
Stockholders' Equity
ABT
ABT
DOW
DOW
Q1 26
$16.0B
Q4 25
$52.1B
$16.0B
Q3 25
$51.0B
$17.5B
Q2 25
$50.6B
$17.2B
Q1 25
$48.8B
$16.8B
Q4 24
$47.7B
$17.4B
Q3 24
$39.8B
$18.3B
Q2 24
$39.3B
$18.3B
Total Assets
ABT
ABT
DOW
DOW
Q1 26
$58.5B
Q4 25
$86.7B
$58.5B
Q3 25
$84.2B
$61.0B
Q2 25
$84.0B
$59.0B
Q1 25
$81.4B
$57.5B
Q4 24
$81.4B
$57.3B
Q3 24
$74.4B
$59.4B
Q2 24
$73.0B
$58.5B
Debt / Equity
ABT
ABT
DOW
DOW
Q1 26
1.12×
Q4 25
0.25×
1.12×
Q3 25
1.01×
Q2 25
0.94×
Q1 25
0.95×
Q4 24
0.30×
0.91×
Q3 24
0.88×
Q2 24
0.87×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABT
ABT
DOW
DOW
Operating Cash FlowLast quarter
$3.3B
Free Cash FlowOCF − Capex
$2.6B
FCF MarginFCF / Revenue
22.9%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
1.87×
TTM Free Cash FlowTrailing 4 quarters
$7.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABT
ABT
DOW
DOW
Q1 26
Q4 25
$3.3B
$284.0M
Q3 25
$2.8B
$1.1B
Q2 25
$2.0B
$-470.0M
Q1 25
$1.4B
$91.0M
Q4 24
$2.9B
$814.0M
Q3 24
$2.7B
$800.0M
Q2 24
$2.0B
$836.0M
Free Cash Flow
ABT
ABT
DOW
DOW
Q1 26
Q4 25
$2.6B
$-284.0M
Q3 25
$2.3B
$563.0M
Q2 25
$1.5B
$-1.1B
Q1 25
$933.0M
$-594.0M
Q4 24
$2.1B
$47.0M
Q3 24
$2.1B
$64.0M
Q2 24
$1.4B
$113.0M
FCF Margin
ABT
ABT
DOW
DOW
Q1 26
Q4 25
22.9%
-3.0%
Q3 25
20.2%
5.6%
Q2 25
13.9%
-11.2%
Q1 25
9.0%
-5.7%
Q4 24
19.6%
0.5%
Q3 24
20.2%
0.6%
Q2 24
13.8%
1.0%
Capex Intensity
ABT
ABT
DOW
DOW
Q1 26
Q4 25
6.0%
6.0%
Q3 25
4.4%
5.7%
Q2 25
4.5%
6.6%
Q1 25
4.7%
6.6%
Q4 24
6.6%
7.4%
Q3 24
5.2%
6.8%
Q2 24
5.1%
6.6%
Cash Conversion
ABT
ABT
DOW
DOW
Q1 26
Q4 25
1.87×
Q3 25
1.70×
18.18×
Q2 25
1.15×
Q1 25
1.07×
Q4 24
0.31×
Q3 24
1.64×
3.74×
Q2 24
1.51×
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons